Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has been given a consensus rating of “Buy” by the eight research firms that are covering the firm, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on the stock in the last year is $12.13.
STRO has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a research report on Friday. JMP Securities restated a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research note on Monday, September 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a report on Friday. Finally, Truist Financial dropped their price objective on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 16th.
View Our Latest Analysis on Sutro Biopharma
Hedge Funds Weigh In On Sutro Biopharma
Sutro Biopharma Stock Up 14.5 %
Sutro Biopharma stock opened at $3.79 on Wednesday. The business’s 50-day moving average price is $3.94 and its 200 day moving average price is $3.93. The firm has a market cap of $310.00 million, a price-to-earnings ratio of -2.02 and a beta of 1.17. Sutro Biopharma has a 52 week low of $2.01 and a 52 week high of $6.13.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.20. The business had revenue of $25.71 million for the quarter, compared to analysts’ expectations of $26.28 million. Sutro Biopharma had a negative net margin of 73.48% and a negative return on equity of 102.06%. Equities analysts expect that Sutro Biopharma will post -2.96 EPS for the current year.
About Sutro Biopharma
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Further Reading
- Five stocks we like better than Sutro Biopharma
- What is Forex and How Does it Work?
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- What is the Dow Jones Industrial Average (DJIA)?
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.